We had the great opportunity to chat with our valued European editorial board member Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden) at EAN 2019. We covered aspects of ageing and dementia that were highlighted across various presentations he was involved with at the congress.
1. What have studies of the dicarboxylate clamp tetratricopeptide motif containing (dcTPR) proteins taught us about Alzheimer’s disease (AD) and other neurodegenerative diseases? (0:04)
2. Could you tell us a little about your recent study on electroencephalography (EEG) in the early detection of synaptic dysfunction in patients with AD? (2:07)
3. What are the implications of these findings for future AD research? (3:15)
4. What are the risks associated with the use of antipsychotic medications in patients with dementia? (4:02)
5. What advice would you give to clinicians considering the use of antipsychotics in their dementia patients? (5:17)
Speaker disclosure: Bengt Winblad has nothing to disclose in relation to this video interview.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Michael Weiner, AD/PD 2021: The Alzheimer’s Disease Neuroimaging Initiative (ADNI)
It was a great pleasure to meet with Michael Weiner (University of California, San Francisco, CA, USA), the Principal Investigator for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), to discuss the initiative’s aims, design and future developments. The abstract entitled ‘Validating Plasma Tests for Amyloid, Tau, and Neurodegeneration Using the Alzheimer’s Disease Neuroimaging Initiative (ADNI)’ was […]
Marwan Sabbagh, AD/PD 2021: Phase 2 MCLENA-1 Trial
TouchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment […]
Yona Levites, AD/PD 2021: Immunotherapeutic Approaches in Alzheimer’s Disease (Part 1)
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA) to discuss immunotherapeutic approaches in Alzheimer’s Disease. Part 2 of the discussion can be viewed here. The abstract entitled ‘Immunotherapeutic approaches in Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!